MedTrace Logo

Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

NCT06487832 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-30

No results posted yet for this study

Summary

The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design. To this end, investigators will compare the effect of the administration of semaglutide versus placebo, followed by an fMRI with administration of intranasal insulin or placebo.

Conditions

Interventions

OTHER

Subcutaneous GLP1-RA

Subcutaneous administration of semaglutide

OTHER

Subcutaneous placebo

Subcutaneous administration of NaCl

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Andreas L. Birkenfeld, MD · Institute for Diabetes research and Metabolic Diseases at the University of Tubingen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2027-07-31
Completion
2027-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06487832 on ClinicalTrials.gov